69 related articles for article (PubMed ID: 34879108)
1. Exploring the impact of the PNPLA3 I148M variant on primary human hepatic stellate cells using 3D extracellular matrix models.
Caon E; Martins M; Hodgetts H; Blanken L; Vilia MG; Levi A; Thanapirom K; Al-Akkad W; Abu-Hanna J; Baselli G; Hall AR; Luong TV; Taanman JW; Vacca M; Valenti L; Romeo S; Mazza G; Pinzani M; Rombouts K
J Hepatol; 2024 Jun; 80(6):941-956. PubMed ID: 38365182
[TBL] [Abstract][Full Text] [Related]
2. The fatty liver disease-causing protein PNPLA3-I148M alters lipid droplet-Golgi dynamics.
Sherman DJ; Liu L; Mamrosh JL; Xie J; Ferbas J; Lomenick B; Ladinsky MS; Verma R; Rulifson IC; Deshaies RJ
Proc Natl Acad Sci U S A; 2024 Apr; 121(18):e2318619121. PubMed ID: 38657050
[TBL] [Abstract][Full Text] [Related]
3. Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women.
Cherubini A; Ostadreza M; Jamialahmadi O; Pelusi S; Rrapaj E; Casirati E; Passignani G; Norouziesfahani M; Sinopoli E; Baselli G; Meda C; Dongiovanni P; Dondossola D; Youngson N; Tourna A; Chokshi S; Bugianesi E; ; Della Torre S; Prati D; Romeo S; Valenti L
Nat Med; 2023 Oct; 29(10):2643-2655. PubMed ID: 37749332
[TBL] [Abstract][Full Text] [Related]
4. The health care experience of adults with metabolic dysfunction-associated steatohepatitis and influence of PNPLA3: A qualitative study.
Stine JG; Medic N; Pettersson B; Venerus M; Blau JE
Hepatol Commun; 2024 Jun; 8(6):. PubMed ID: 38780312
[TBL] [Abstract][Full Text] [Related]
5. The fatty liver disease-causing protein PNPLA3-I148M alters lipid droplet-Golgi dynamics.
Sherman DJ; Liu L; Mamrosh JL; Xie J; Ferbas J; Lomenick B; Ladinsky MS; Verma R; Rulifson IC; Deshaies RJ
bioRxiv; 2023 Oct; ():. PubMed ID: 37873239
[TBL] [Abstract][Full Text] [Related]
6. The PNPLA3 I148M variant increases ketogenesis and decreases hepatic de novo lipogenesis and mitochondrial function in humans.
Luukkonen PK; Porthan K; Ahlholm N; Rosqvist F; Dufour S; Zhang XM; Lehtimäki TE; Seppänen W; Orho-Melander M; Hodson L; Petersen KF; Shulman GI; Yki-Järvinen H
Cell Metab; 2023 Nov; 35(11):1887-1896.e5. PubMed ID: 37909034
[TBL] [Abstract][Full Text] [Related]
7. A patient-based iPSC-derived hepatocyte model of alcohol-associated cirrhosis reveals bioenergetic insights into disease pathogenesis.
Mukhopadhyay B; Marietta C; Shen PH; Oiseni A; Mirshahi F; Mazzu M; Hodgkinson C; Winkler E; Yuan Q; Miranda D; Kunos G; Sanyal AJ; Goldman D
Nat Commun; 2024 May; 15(1):2869. PubMed ID: 38693144
[TBL] [Abstract][Full Text] [Related]
8. Author Correction: Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women.
Cherubini A; Ostadreza M; Jamialahmadi O; Pelusi S; Rrapaj E; Casirati E; Passignani G; Norouziesfahani M; Sinopoli E; Baselli G; Meda C; Dongiovanni P; Dondossola D; Youngson N; Tourna A; Chokshi S; Bugianesi E; ; Della Torre S; Prati D; Romeo S; Valenti L
Nat Med; 2024 Apr; 30(4):1212. PubMed ID: 38267549
[No Abstract] [Full Text] [Related]
9. Human hepatocyte PNPLA3-148M exacerbates rapid non-alcoholic fatty liver disease development in chimeric mice.
Kabbani M; Michailidis E; Steensels S; Fulmer CG; Luna JM; Le Pen J; Tardelli M; Razooky B; Ricardo-Lax I; Zou C; Zeck B; Stenzel AF; Quirk C; Foquet L; Ashbrook AW; Schneider WM; Belkaya S; Lalazar G; Liang Y; Pittman M; Devisscher L; Suemizu H; Theise ND; Chiriboga L; Cohen DE; Copenhaver R; Grompe M; Meuleman P; Ersoy BA; Rice CM; de Jong YP
Cell Rep; 2022 Sep; 40(11):111321. PubMed ID: 36103835
[TBL] [Abstract][Full Text] [Related]
10. IL-6/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease.
Park J; Zhao Y; Zhang F; Zhang S; Kwong AC; Zhang Y; Hoffmann HH; Bushweller L; Wu X; Ashbrook AW; Stefanovic B; Chen S; Branch AD; Mason CE; Jung JU; Rice CM; Wu X
J Hepatol; 2023 Jan; 78(1):45-56. PubMed ID: 36049612
[TBL] [Abstract][Full Text] [Related]
11. PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date.
Cherubini A; Casirati E; Tomasi M; Valenti L
Expert Opin Ther Targets; 2021 Dec; 25(12):1033-1043. PubMed ID: 34904923
[TBL] [Abstract][Full Text] [Related]
12. Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches.
Mahmoudi SK; Tarzemani S; Aghajanzadeh T; Kasravi M; Hatami B; Zali MR; Baghaei K
Eur J Med Res; 2024 Mar; 29(1):190. PubMed ID: 38504356
[TBL] [Abstract][Full Text] [Related]
13. Human Hepatic Stellate Cells: Isolation and Characterization.
Liu X; Brenner DA; Kisseleva T
Methods Mol Biol; 2023; 2669():221-232. PubMed ID: 37247063
[TBL] [Abstract][Full Text] [Related]
14. Hepatic stellate cell activation markers are regulated by the vagus nerve in systemic inflammation.
Ahmed O; Caravaca AS; Crespo M; Dai W; Liu T; Guo Q; Leiva M; Sabio G; Shavva VS; Malin SG; Olofsson PS
Bioelectron Med; 2023 Mar; 9(1):6. PubMed ID: 36997988
[TBL] [Abstract][Full Text] [Related]
15. PNPLA3 downregulation exacerbates the fibrotic response in human hepatic stellate cells.
Rady B; Nishio T; Dhar D; Liu X; Erion M; Kisseleva T; Brenner DA; Pocai A
PLoS One; 2021; 16(12):e0260721. PubMed ID: 34879108
[TBL] [Abstract][Full Text] [Related]
16. PNPLA3 I148M Up-Regulates Hedgehog and Yap Signaling in Human Hepatic Stellate Cells.
Bruschi FV; Tardelli M; Einwallner E; Claudel T; Trauner M
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33218077
[TBL] [Abstract][Full Text] [Related]
17. PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells.
Pirazzi C; Valenti L; Motta BM; Pingitore P; Hedfalk K; Mancina RM; Burza MA; Indiveri C; Ferro Y; Montalcini T; Maglio C; Dongiovanni P; Fargion S; Rametta R; Pujia A; Andersson L; Ghosal S; Levin M; Wiklund O; Iacovino M; Borén J; Romeo S
Hum Mol Genet; 2014 Aug; 23(15):4077-85. PubMed ID: 24670599
[TBL] [Abstract][Full Text] [Related]
18. The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells.
Bruschi FV; Claudel T; Tardelli M; Caligiuri A; Stulnig TM; Marra F; Trauner M
Hepatology; 2017 Jun; 65(6):1875-1890. PubMed ID: 28073161
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
